AbbVie Inc.

Read together, the filings show a company with growing revenue and strong operating cash generation, but thinner profit to shareholders and a heavily leveraged balance sheet. The Beneish M-Score of -2.860 is below the -1.78 threshold and is not in the elevated manipulation-risk zone. That is a screening result and does not rule out questions about individual line items. The Piotroski F-Score is 7 of 8 computable signals, which points to generally sound fundamentals on the measures it tests. The Altman Z″-Score of -0.34 is in the distress zone. It is a broad solvency screen, and with $64.5 billion of long-term debt and large intangible assets it deserves attention, though it is not a forecast of default. The Fog Index of 15.61 falls in the hard-to-read band, so the MD&A requires a careful read. Operating cash flow of $19.03 billion equals 4.50 times net income, meaning cash earnings run well above accounting profit, which may partly reflect non-cash charges such as the amortization noted in the 10-Q. The pipeline story is mixed. The Phase 3 EPCORE DLBCL-1 trial for Epkinly did not show a statistically significant overall survival improvement, while EPCORE DLBCL-4 met its progression-free survival endpoint. The Boey complete response letter cited manufacturing process questions rather than safety or efficacy concerns. The $100 billion U.S. investment pledge and the three-year tariff and price-mandate exemption are significant but depend on ongoing government arrangements. Readers may want to look at the full Item 1A risk factors, since the excerpt provided is mostly the table of contents and business description.

Catalyst.According to the 10-Q MD&A, AbbVie's six-month 2026 results show worldwide net revenues of $32.0 billion, up 11% on a reported basis and 10% at constant currency, with diluted earnings per share of $2.42. Management points to a run of approvals, including Skyrizi for children with plaque psoriasis in the U.S. and Europe, Venclexta combined with acalabrutinib for previously untreated CLL, and Rinvoq approvals in the EU for vitiligo and alopecia areata. The 2025 10-K shows revenues of $61.16 billion, up 8.6% from $56.33 billion, and operating income of $15.07 billion, up from $9.14 billion.

Hidden risk.The most material tension is between revenue growth and what reaches shareholders. Full-year 2025 net income was $4.23 billion, slightly below $4.28 billion in 2024, even though operating income rose to $15.07 billion. The 10-Q cites $3.4 billion of intangible asset amortization and $3.9 billion of contingent consideration fair value changes in the first half of 2026. Equity was negative $3.27 billion at year-end 2025 after $3.33 billion a year earlier, and long-term debt stood at $64.5 billion. The Altman Z″-Score of -0.34 falls in the distress zone, which is a screening signal rather than a forecast. Pricing pressure also looms, since Botox was selected for government-set Medicare prices beginning in 2028.